Andrew Kelada, MD
Pulmonary Disease · Roseville, CANPI 1417488123
Payments from drug & device makers
Across 23 payments — averaging $58.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$152
- Astellas Pharma US Inc$150
- Pulmonx Corporation$140
- Amgen$125
- Regeneron Healthcare Solutions, Inc.$125
- Sanofi$125
- plus $539 from 11 others
What the payments were for
- Food & beverage$1,20689%
- Education$15011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inari Medical, Inc. | 2 | $152 |
| Astellas Pharma US Inc | 2 | $150 |
| Pulmonx Corporation | 1 | $140 |
| Amgen | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Sanofi | 1 | $125 |
| Shionogi Inc | 1 | $125 |
| Verona Pharma, Inc. | 1 | $111 |
| Novo Nordisk | 3 | $59 |
| Pfizer | 2 | $46 |
| Intra-sana Laboratories | 2 | $43 |
| Bayer | 1 | $35 |
| Aimmune Therapeutics, Inc. | 1 | $30 |
| AbbVie | 1 | $30 |
| Biogen | 1 | $27 |
| Lilly USA, LLC | 1 | $17 |
| RGH Enterprises LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,356 in reported general payments places this provider in the 45th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 25 | $11,445 |
| BreynaBudesonide/Formoterol Fumarate | 61 | $8,004 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Roseville
- Toby MaherLos Angeles$27.6M
- David PhamWestminster$5.9M
- Andrew WachtelLos Angeles$5.9M
- Aaron WeinbergIrvine$5.1M
- Michael RothLos Angeles$4.5M
- Namita SoodSacramento$3.7M
- Edward FedermanSan Diego$3.6M
- Sanjay VadgamaSherman Oaks$3.3M
- Rajan SaggarLos Angeles$3.3M
- Samuel LouieSacramento$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.